*5.6. Statistical Analysis*

Data are presented as the mean ± S.E.M unless indicated otherwise and statistical significance was calculated for at least three independent experiments employing the Student's *t*-test, using GraphPad Prism 8.0 software (GraphPad Software, Inc., San Diego, CA, USA). *p*-values < 0.05 were considered to be statistically significant.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10 .3390/toxins13120913/s1. Table S1: GenBank accession numbers of serpins used in the phylogenetic analysis; Figure S1: CD spectrum analysis by the BesSel program; Figure S2: Cartoon representations of the secondary elements in the active model of Dromaserpin; Figure S3: Ramachandran

plot of Dromaserpin Model with an exposed RCL, generated by MolProbity program; Figure S4: Ramachandran plot of Dromaserpin Model with an inserted RCL, generated by MolProbity program. References [32,34,47,50,71–78] are cited in the supplementary materials.

**Author Contributions:** Conceptualization, H.A., C.B., Y.M. and F.F.; Data curation, H.A. and M.R.F.; Formal analysis, H.A., M.R.F., E.C. and F.F.; Funding acquisition, A.M.C.-T. and F.F.; Investigation, H.A.; Methodology, M.B.G.; Project administration, A.M.C.-T., A.B. and F.F.; Resources, C.B.; Software, M.R.F.; Supervision, Y.M. and F.F.; Validation, M.B.G. and F.F.; Writing–original draft, H.A.; Writing– review & editing, H.A., M.R.F., M.B.G., Y.M. and F.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)—Finance Code 001; by FAPESP (CETICS: 2013/07467–1) and Fundação Butantan. C.B. received the European Union within ESIF in frame of Operational Programme Research, Development and Education (project no. CZ.02.2.69/0.0/0.0/20\_079/0017809).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** The Factor IXa Kit was generously provided by Elizabeth Angelica Martins from the Laboratory of Recombinant Biologics, Butantan Institute. Kallikrein was kindly provided by Benedito Prezotto from the Laboratory of Pharmacology, Butantan Institute. Heparin was kindly provided by Durvanei Augusto Maria from the Laboratory of Development and Innovation, Butantan Institute. We would like to thank Deborah Glassman for her English corrections and comments on the manuscript. We are grateful to Karem Jridi, a graphic designer at the NGC Company (New Generation Concept) in Tunisia, for the figure editing.

**Conflicts of Interest:** The authors declare no conflict of interest.
